New Data Validate Vidaza(R) Response Rates In MDS And Report Results In AML
Tue, 26 Dec 2006 08:00 AM EST
... Pharmion Corporation (Nasdaq: PHRM) announced new data presented today at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, December 9-12, 2006) on Vidaza(R) (azacitidine for injectable suspension) as single-agent therapy for the treatment of myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML). [click link for full article] ...
Related Topics
- Data & Statistics
- Data Analysis
- National Data
- Disaster Response
- Azacitidine Injection
- Mining
- Carcinogens
- Emergency Preparedness & Response
- Surgeon General's Reports on Tobacco
- Morbidity & Mortality Weekly Report
- Youth Violence
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Relaxation Response
- Decreased immune response
- Logging
- Chemical Safety
- Visualization
- Myelodysplastic Syndromes
- Influenza Surveillance Data
- General Health

Not Signed In -

